Restoring Bioenergetics in the Traumatized Eye: The Emergence of Mitochondrial Implantation as a Treatment for Acute Ocular Injury

3.1. Mesenchymal Stem Cells as Optimal Mitochondrial Donors
30

MSCs’ robust proliferative potential and sustained telomerase activity compared to differentiated somatic cells [37] permits efficient in vitro expansion of MSC without premature cellular aging, yielding a higher count of functional mitochondria. These MSC-isolated mitochondria tend to exhibit preserved membrane potential and efficient oxidative phosphorylation [38], and when transplanted they have been shown to reduce ROS accumulation, restore oxidative phosphorylation, and improve cellular survival in injured tissues [39]. Beyond transplantation of isolated mitochondria, MSCs are capable of active mitochondrial transfer through TNTs, EVs, or direct cell–cell contact [40]. This capability highlights their biological compatibility as mitochondrial donors and suggests that exogenously isolated mitochondria retain functional properties optimized for cellular uptake and integration.

3.2. Comparative Analysis: Isolated Organelle Injection vs. Whole Cell-Based Transfer
31

There are two primary strategies for using MSC in mitochondrial transplantation: injection of isolated mitochondria and direct MSC transplantation. Both approaches aim at restoring cellular bioenergetics in damaged ocular tissue, yet they differ in mechanisms, timing, and complexity.

32

For injection of isolated mitochondria, mitochondria are extracted from MSCs using several purification and centrifugation protocols [41]. The isolated mitochondria are then suspended in a respiration-promoting buffer and delivered directly into the ocular tissue through an intravitreal injection. This delivery allows for rapid mitochondrial uptake that immediately enhances the bioenergetics of the recipient cells [42]. However, this strategy is strongly dependent on mitochondrial viability post isolation. Once mitochondria are removed from their native environment, they become particularly vulnerable to oxidative stress and efficient cellular uptake is not guaranteed. Hence, injected mitochondria can provide rapid intervention yet may be limited due to its transient effects.

33

Another strategy is the direct transplantation of MSC into the ocular tissue. In this situation, MSC work as a responsive mitochondrial donor, reacting to local tissue injury and actively transfer mitochondria to damaged cells through TNTs, gap junctions, and EVs [38]. This approach allows for sustained mitochondrial transfer and additional cytoprotective benefits, including the secretion of anti-inflammatory cytokines. MSCs have an intrinsic mitochondrial quality control system that ensures the transfer of functional organelles. However, the survival and behavior of transplanted MSCs within the ocular environment is variable and potentially influenced by immune response.

34

Overall, both strategies provide promising approaches to mitochondrial transplantation as a therapeutic strategy in cases of ocular injury. The choice between them is predominantly dependent on clinical context and therapeutic timeline, as MSC-mediated delivery offers a more sustained long-term approach whilst injection of isolated mitochondria provides a more rapid intervention.

35

Ocular Delivery Routes for Acute Injury (Table 1 and Figure 2): The eye’s unique anatomy allows for targeted delivery depending on the site of the acute injury. Route selection for the posterior segment must also take into account the integrity of the blood–retinal barrier (BRB). As illustrated in Figure 2, mitochondrial dysfunction can compromise this barrier: in human retinal pigment epithelial (ARPE-19) cells exposed to high glucose, mitochondrial dysfunction was accompanied by loss of outer BRB integrity, and pharmacological antagonism of the α1D adrenergic receptor protected against both [43]. A compromised BRB may, in turn, alter the local pharmacokinetics and tissue penetration of intravitreally or subretinally delivered mitochondria.

3.3. Non-Invasive Procurement: Urine-Derived Stem Cells as an Emerging Source
36

Selecting an optimal donor source is critical for the success of mitochondrial transplantation. Urine-derived stem cells (USC) represent a paradigm shift in this regard due to their ready availability, scalability, ethics, and non-invasive procurement of robust mitochondria. When compared to other mesenchymal sources, USCs demonstrate superior expansion rates and a greater metabolic profile [35]. In the context of acute ocular trauma, these cells can be utilized either as a source for isolated organelle extraction or as live delivery vehicles. By leveraging routes such as intravitreal or subconjunctival injection, USC-derived mitochondria can be delivered directly to the site of metabolic collapse, offering a rapid intervention to prevent irreversible vision loss.

3.4. Ocular Delivery Routes and Critical Evaluation of Translational Evidence
37

Topical Administration: Topical delivery currently has the strongest evidence for anterior segment applications (e.g., corneal epithelial repair). However, significant biological questions remain regarding mitochondrial stability within tear fluid, interactions with mucins, residence time, dose reproducibility, and penetration beyond the epithelial barrier.

38

Subconjunctival Administration: Subconjunctival injection is frequently proposed, but direct evidence demonstrating successful delivery of isolated mitochondria into the corneal stroma, limbal stem-cell niche, or intraocular tissues is currently lacking (conceptual/extrapolated).

39

Intravitreal & Subretinal Administration: Intravitreal delivery has been demonstrated in preclinical retinal and RGC models, yet stability in vitreous humor, cell-type specificity, clearance kinetics, and inflammatory risks require further characterization.

4. Applications for Specific Ocular Pathologies and Evidence Stratification
40

Acute ocular injuries trigger a cascade of bioenergetic failure characterized by acute ATP depletion, mitochondrial Ca2+ overload with mPTP opening, membrane potential collapse, and oxidative stress. However, current clinical management of acute trauma focuses on stabilization rather than cellular metabolic rescue. Standard clinical protocols entail immediate copious irrigation and pH normalization for chemical insults, combined with cycloplegia, matrix metalloproteinase inhibition (e.g., topical tetracyclines or citrate), anti-inflammatory modulation, and prophylactic antimicrobial coverage, followed by staged reconstructive surgical procedures when necessary. In addition to corticosteroids and conventional NSAIDs, emerging therapies seek to simultaneously target inflammation and oxidative stress. Pittalà et al. [44] developed hybrid compounds combining caffeic acid phenethyl ester (CAPE), a naturally occurring antioxidant and anti-inflammatory molecule, with traditional NSAIDs. In an experimental ocular inflammation model, CAPE-NSAID hybrids (particularly a CAPE–aspirin derivative) significantly reduced clinical inflammatory scores and decreased levels of PGE2 and TNF-α in aqueous humor. Although these compounds do not involve mitochondrial transplantation, they illustrate how modulation of the inflammatory and oxidative microenvironment may complement future regenerative organelle therapies.

41

To rigorously evaluate the therapeutic potential of mitochondrial transfer, evidence must be stratified by direct ocular testing, non-ocular model extrapolation, mechanistic plausibility, and speculative clinical translation.

4.1. Direct Evidence from Ocular Models
42

Corneal Epithelium: Direct application of isolated mitochondria or stem cell co-culture in corneal injury models demonstrates uptake by damaged corneal epithelial cells. Exogenous organelle delivery accelerates epithelial wound closure, restores cellular energy, and attenuates myofibroblast-driven fibrotic scarring [41].

43

Retinal Ganglion Cells (RGCs) & Optic Nerve: RGCs are acutely vulnerable to traumatic optic neuropathy (TON) and optic nerve crush injuries [45], owing to their exceptionally high metabolic demands [8,46]. Preclinical intravitreal administration demonstrates that exogenous mitochondria are internalized by RGCs, preserving cell viability, maintaining axonal integrity, and stabilizing oxidative phosphorylation [47].

44

Retinal Ischemia–Reperfusion (I/R) Injury: Acute intraocular pressure (IOP) spikes or vascular occlusion models induce severe transient ischemia followed by reperfusion-induced ROS bursts [18,48]. Direct mitochondrial transplantation during or immediately following the ischemic window functions as a metabolic and antioxidant buffer, significantly reducing retinal tissue damage/infarction and preserving electrophysiological function on electroretinography (ERG).

4.2. Evidence Derived from Non-Ocular Tissues
45

Given that mitochondrial transplantation in ophthalmology is an emerging field, key foundational mechanisms and organelle transfer proofs-of-concept are adapted from established non-ocular injury models:

46

Cardiac Models: Ischemia–reperfusion and myocardial infarction models demonstrate that direct injection of autologous mitochondria restores ATP, reduces infarct size, and recovers mechanical contraction [42,49].

47

Neurologic & Spinal Cord Models: Focal cerebral ischemia and spinal cord crush studies confirm that exogenous mitochondrial uptake reduces neuroinflammation, preserves neuronal integrity, and restores locomotor function [50,51].

48

Pulmonary Models: Acute lung injury models demonstrate that mesenchymal stem cell (MSC)-mediated transfer via microvesicles or tunneling nanotubes (TNTs) mitigates alveolar–capillary barrier disruption [52].

4.3. Mechanistic Plausibility
49

Across both ocular and systemic systems, the primary bioenergetic rationale for mitochondrial transfer rests on four core pillars:

50

ATP Restoration: Bypassing damaged endogenous electron transport chain complexes to rapidly restore oxidative phosphorylation.

51

ROS Reduction: Suppressing excessive reactive oxygen species production and clearing oxidative stress markers.

52

Membrane Potential Rescue: Re-establishing the mitochondrial membrane potential (ΔΨ_m) to inhibit Cytochrome c release and block downstream caspase-dependent apoptotic cascades.

53

Ca2+ Buffering and mPTP Stabilization: Because mitochondrial Ca2+ uptake is driven by ΔΨm, a pool of transplanted, well-polarized mitochondria could, in principle, increase the capacity of injured cells to sequester excess cytosolic Ca2+ and limit the matrix Ca2+ overload that triggers mPTP opening in endogenous mitochondria [17,19]. Experimental support for this concept currently comes from muscle pathology. In dystrophin-deficient mdx mice, which exhibit chronic Ca2+ dysregulation, repeated intramuscular injection of mitochondria isolated from healthy muscle reduced mitochondrial Ca2+ overload and Ca2+ deposits in skeletal muscle, and the authors proposed that the transplanted organelles take up excess Ca2+; notably, the treatment did not restore the Ca2+ retention capacity of the host mitochondria [53]. Whether transplanted mitochondria can normalize Ca2+ homeostasis in corneal, retinal, or optic nerve cells has not yet been tested, and the possibility that donor mitochondria themselves become Ca2+-overloaded and undergo permeability transition in the post-injury environment must also be considered. Future ocular studies should therefore include direct measurements of cytosolic and mitochondrial Ca2+, mitochondrial Ca2+ retention capacity, and mPTP opening alongside conventional bioenergetic endpoints.

4.4. Proposed or Speculative Clinical Applications
54

While acute trauma represents the primary experimental target, mitochondrial transplantation is conceptually proposed for chronic or complex degenerative conditions:

55

Ocular Surface Reconstruction: Restoring chronic limbal stem cell deficiency following severe chemical or thermal burns [54,55].

56

Glaucomatous Neuroprotection: Supplementing chronic bioenergetic deficits in RGCs subject to persistent IOP stress [21,46].

57

Degenerative Retinal Pathologies: Proposed applications in Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy to mitigate chronic RPE and vascular endothelial degeneration.

4.5. Ocular Compartments with Limited or No Direct Evidence
58

To maintain scientific rigor, it is critical to highlight that several anatomical compartments currently lack direct in vivo evidence for isolated mitochondrial transplantation (Table 2 and Table 3):

59

Limbal Stroma & Deep Corneal Stroma: Lacks established delivery and engraftment data.